The goal of our studies is to understand the mechanisms that regulate viral late gene expression and genome amplification during the productive life cycle of oncogenic human papillomaviruses (HPVs). Papillomaviruses are small DNA viruses that induce a variety of proliferative epithelial lesions. Infection by papillomaviruses occurs into the basal cells of the epithelia where genomes are established as low copy episomes. The life cycle of papillomaviruses is tightly linked to epithelial differentiation with the induction of late gene expression, genome amplification and assembly of virions restricted to suprabasal cells. My laboratory first developed methods to grow human papillomaviruses in tissue culture and extended these techniques to synthesize HPVs from cloned DNA. These methods have allowed for a detailed genetic analysis of the productive life cycle of human papillomaviruses. In the recent grant period we have identified sequences within the URR and the E6/E7 coding sequences that regulate late gene expression in differentiated cells. Our studies have also identified E2F2, C/EBP2, C/EBP1 as prime candidates to be the major regulators of late gene expression. Additional work demonstrated that HPV proteins activate caspases upon differentiation and that this is necessary for efficient genome amplification. We further determined that caspases target the E1 proteins and that this facilitates amplification. In this grant, I propose to investigate how late gene expression and amplification are regulated by asking the following questions: 1) How is HPV late gene expression regulated in differentiating epithelia? How do E2F2, C/EBP2, C/EBP1 function in the activation of late expression? Do viral proteins play a role in activating late expression independent of their role in mediating amplification? 2) What mechanisms regulate differentiation-dependent amplification? How do the caspase cleaved forms of E1 and E2 contribute to genome amplification in differentiating cells?

Public Health Relevance

Cervical cancer is the second leading cause of death by cancer in women worldwide and the overall 5-year survival rate is approximately 50%. In 2006, the FDA approved a prophylactic Human Papillomavirus (HPV) vaccine but this vaccine will not protect women against all the HPV types that cause cervical cancer. In addition, it is ineffective in clearing existing lesions as it only blocks initial infection. This study examines how the productive life cycle of these viruses is regulated through changes in viral gene expression and replication. This is an area of high importance as it can identify new targets for anti-viral treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA059655-19
Application #
8213481
Study Section
Virology - B Study Section (VIRB)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
1993-09-30
Project End
2014-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
19
Fiscal Year
2012
Total Cost
$302,544
Indirect Cost
$102,184
Name
Northwestern University at Chicago
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Pattabiraman, Chitra; Hong, Shiyuan; Gunasekharan, Vignesh K et al. (2014) CD66+ cells in cervical precancers are partially differentiated progenitors with neoplastic traits. Cancer Res 74:6682-92
Hong, Shiyuan; Laimins, Laimonis A (2013) The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation. PLoS Pathog 9:e1003295
Bodily, Jason M; Mehta, Kavi P M; Laimins, Laimonis A (2011) Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res 71:1187-95
Bodily, Jason; Laimins, Laimonis A (2011) Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 19:33-9
Melar-New, Marta; Laimins, Laimonis A (2010) Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol 84:5212-21
Fradet-Turcotte, Amelie; Moody, Cary; Laimins, Laimonis A et al. (2010) Nuclear export of human papillomavirus type 31 E1 is regulated by Cdk2 phosphorylation and required for viral genome maintenance. J Virol 84:11747-60
Wooldridge, Tonia R; Laimins, Laimonis A (2008) Regulation of human papillomavirus type 31 gene expression during the differentiation-dependent life cycle through histone modifications and transcription factor binding. Virology 374:371-80
Senechal, Helene; Poirier, Guy G; Coulombe, Benoit et al. (2007) Amino acid substitutions that specifically impair the transcriptional activity of papillomavirus E2 affect binding to the long isoform of Brd4. Virology 358:10-7
Moody, Cary A; Fradet-Turcotte, Amelie; Archambault, Jacques et al. (2007) Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc Natl Acad Sci U S A 104:19541-6
Hindmarsh, Patrick L; Laimins, Laimonis A (2007) Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry. Virol J 4:19

Showing the most recent 10 out of 20 publications